Klow80

Overview

The Klow80 peptide blend is a four-component co-lyophilized preparation combining GHK-Cu, KPV, BPC-157 and TB-500 in a single 80mg research vial. Torsena supplies it to qualified laboratories across the European Union. Furthermore, we hold stock in Europe, so orders ship without intra-EU customs delay.

Lot & Supply Format

• Component purity. Each peptide is sourced at typically ≥99% purity against its own raw-material CoA, prior to blending.
• Formulation. Mannitol-free, so no bulking agents or buffer salts dilute the material.
• Presentation. Co-lyophilized preparation, sealed in glass research vials.
• Quantities. Single vials as standard, though we also quote bulk on request.
• Shipping. Dispatched from Europe, and always with temperature-appropriate packaging.

What is the Klow80 peptide blend?

The Klow80 peptide blend combines four separately studied peptides in one co-lyophilized vial. Each component acts through a distinct pathway, so the preparation exists for protocols examining several pathways in parallel rather than for isolating any single one.

GHK-Cu, 50mg. The copper(II) complex of the naturally occurring tripeptide glycyl-histidyl-lysine. Pickart first isolated it from human plasma in 1973. Research examines extracellular matrix remodeling, collagen and glycosaminoglycan synthesis, and angiogenesis signaling. Notably, Pickart and colleagues have reported gene expression effects across tissue-repair, antioxidant and anti-inflammatory pathways, with the frequently quoted figure of roughly 4,000 human genes being an extrapolation from Connectivity Map analysis rather than a direct count.

KPV, 10mg. The C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone. Research examines NF-κB inflammatory signaling and melanocortin-mediated immune modulation.

BPC-157, 10mg. A 15-amino acid pentadecapeptide derived from a gastric protein sequence. Research examines cytoprotective signaling, nitric oxide system modulation, and VEGF-associated angiogenesis pathways.

TB-500, 10mg. A synthetic thymosin beta-4 related peptide. Research examines actin cytoskeleton dynamics, cell migration signaling, and inflammatory mediator modulation.

Because all four arrive in a single vial, one reconstitution prepares the full preparation. Therefore preparation steps and open-vial handling both drop compared with combining four separate products.

Supplied exclusively for in-vitro and ex-vivo research by qualified laboratories. Not intended for human or animal administration.

Klow80 Peptide Blend Component Reference Data

Note that GHK-Cu carries CAS 89030-95-5 as the copper(II) complex. The copper-free tripeptide GHK is a separate entity with CAS 49557-75-7 and a molecular weight of 340.38 against roughly 402 for the complex. Because copper coordination underpins most of the documented activity, the distinction matters when comparing published studies.

Handling the Copper Component

Copper(II) is redox-active, and that has practical consequences for a preparation containing 50mg of a copper complex alongside other peptides.

• Reducing agents. Avoid them, since they will act on the copper centre.
• Air exposure. Minimise open-vial time, because copper can catalyse oxidation of peptides in the same solution.
• Fresh preparation. Prepare working dilutions close to use rather than storing dilute solutions.
• Blue tint. Expected. It reflects the copper content and is not a sign of contamination.

Researchers running long incubations should account for copper-catalysed oxidation as a variable, particularly where oxidation-sensitive residues are present in the other components.

Reconstitution & Storage

• Solvent. Sterile water or a suitable aqueous buffer.
• Short-term storage. 2-8°C for reconstituted aliquots.
• Long-term storage. Aliquot, then freeze at -20°C.
• Freeze-thaw. Avoid repeated cycles, since each one costs integrity.

Keep lyophilized material at -20°C and protect it from light. Furthermore, let vials warm to room temperature before opening, because condensation otherwise pulls moisture into the powder. Otherwise follow your institutional SOPs.

Klow80 peptide blend specifications

Analytical Documentation

We provide documentation on request for institutional procurement. However, note what a co-lyophilized preparation can and cannot evidence.

• Component purity. Established on raw materials before blending, since HPLC on a finished blend returns a mixture chromatogram rather than independent per-component figures.
• Identity. Mass spectrometry resolves the component masses in the preparation.
• Physical checks. Namely appearance and solubility verification.

Researchers requiring independently verified purity for a single compound should order that compound on its own rather than as part of a preparation. Therefore we are happy to quote the standalone components instead where a protocol demands it.

Why Choose Torsena

• Documentation. We send available batch documentation on request.
• No fillers. Mannitol-free, so nothing dilutes the material you paid for.
• EU distribution. We ship from European stock, and therefore intra-EU orders clear no customs.
• Direct contact. You reach the team directly, rather than a ticket queue.

Frequently Asked Questions

What is in the Klow80 peptide blend?
Four components in one 80mg vial: GHK-Cu at 50mg, plus KPV, BPC-157 and TB-500 at 10mg each. All four are co-lyophilized, so a single reconstitution prepares the whole preparation.

What is the correct CAS number for GHK-Cu?
The copper(II) complex is 89030-95-5, with a molecular weight of roughly 402 and the formula C14H22CuN6O4. The copper-free tripeptide GHK is a separate entity: CAS 49557-75-7, molecular weight 340.38. Note that many listings cite the free-peptide CAS for the copper complex, which is incorrect, and because copper coordination underpins most documented activity the distinction matters when reading studies.

Why is the reconstituted solution blue?
The copper content of the GHK-Cu component. Copper(II) complexes are characteristically blue, so the tint is expected and is not an indicator of contamination or degradation.

Can per-component purity be verified on the blend itself?
No. Reverse-phase HPLC on a co-lyophilized four-component preparation returns a mixture chromatogram, so independent purity figures for each peptide can only be established on the raw materials before blending. Researchers needing independently verified purity on a single compound should order that compound standalone.

Does the copper affect the other components?
Potentially, and protocols should account for it. Copper(II) is redox-active and can catalyse oxidation of peptides sharing the same solution. Therefore avoid reducing agents, minimise open-vial time, and prepare working dilutions close to use rather than storing them dilute.

Why use a blend rather than separate compounds?
A single reconstitution reduces preparation steps and handling. However, a fixed-ratio preparation cannot attribute an observed effect to any individual component, so protocols designed to isolate a mechanism need the standalone compounds instead.

Related Research Compounds

• GHK-Cu. The standalone copper tripeptide, and therefore the right choice where a protocol needs to isolate its contribution.

Otherwise, browse the full catalog at the Torsena shop.